Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial

Published:2022-04-05 Issue:12 Volume:128 Page:2281-2287
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kiyota Naomi¹^ORCID,Tahara Makoto²,Robinson Bruce³,Schlumberger Martin⁴,Sherman Steven I.⁵,Leboulleux Sophie⁴,Lee Eun Kyung⁶^ORCID,Suzuki Takuya⁷,Ren Min⁸,Fushimi Kazuma⁷,Wirth Lori J.⁹^ORCID

Affiliation:

1. Kobe University Hospital Cancer Center Kobe Japan

2. National Cancer Center Hospital East Kashiwa Japan

3. University of SydneyRoyal North Shore Hospital St Leonards New South Wales Australia

4. Gustave‐Roussy and University Paris Saclay Villejuif France

5. The University of Texas MD Anderson Cancer Center Houston TX USA

6. Graduate School of Cancer Science and PolicyNational Cancer Center Goyang‐si Korea

7. Eisai Co., Ltd. Tokyo Japan

8. Eisai Inc. Nutley NJ USA

9. Harvard Medical School, Massachusetts General Hospital Boston MA USA

Funder

Eisai

Merck Sharp and Dohme

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34181

Reference18 articles.

1. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies

2. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma

3. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

4. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation

5. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Prognostication in Patients with Differentiated Thyroid Cancer and Distant Metastases: A SEER Population-Based Study;Thyroid®;2024-07-01

2. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers;Clinical Cancer Research;2024-06-26

3. Programmed Death Ligand-1 and Tumor Burden Score Dictate Treatment Responses in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma;Cancers;2024-04-30

4. State of the Art in 3D Culture Models Applied to Thyroid Cancer;Medicina;2024-03-22

5. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study;Endocrine;2024-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3